Zogenix

Zogenix was a global biopharmaceutical company founded in 2006 and headquartered in Emeryville, California, focused on developing and commercializing therapies for rare diseases. Its lead product, FINTEPLA (fenfluramine), was approved by the FDA and EMA for treating seizures associated with Dravet syndrome, with the company pursuing additional indications for Lennox-Gastaut syndrome and CDKL5 deficiency disorder. UCB acquired Zogenix in a deal valued at up to $1.9 billion, completing the tender offer on March 7, 2022, after which Zogenix became a wholly-owned UCB subsidiary and was delisted from NASDAQ.